According to results of randomised controlled trials, when CDK4/6 inhibitor added to letrozole in the first line treatment of HR positive Her2 negative advanced breast cancer patients, median PFS times were doubled and also median OS was improved. This evidence concerns the gene ERBB2 and breast cancer.